Risk of Clostridium difficile Infection with the Use of a Proton Pump Inhibitor for Stress Ulcer Prophylaxis in Critically Ill Patients
1
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Background/Aims: Proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs) are commonly prescribed for stress ulcer prophylaxis (SUP) in critically ill patients. Several studies have suggested that the use of PPIs is a potential risk factor for Clostridium difficile infection (CDI). We compared the incidences of CDI in the PPI group and H2RA group for SUP in critically ill patients. Methods: From August 2005 to July 2012, the incidences of CDI were retrospectively analyzed in patients who were admitted directly to intensive care units and stayed for more than 3 days. SUP-related CDI was defined as a CDI diagnosed during the SUP period. Patient clinical data were analyzed to identify potential risk factors for SUP-related CDI. Results: Of the 1,005 patients enrolled (444 patients received PPI and 561 received H2RA), 38 (3.8%) were diagnosed with SUP-related CDI. The incidence of SUP-related CDI was considerably higher in patients who received PPI than in those who received H2RA (6.7% vs 1.8%). PPI use for SUP (odds ratio [OR], 3.3; confidence interval [CI], 1.5 to 7.1; p=0.003) and diabetes mellitus (OR, 2.3; CI, 1.2 to 4.7; p=0.019) were independent risk factors for SUP-related CDI. Conclusions: PPI therapy is associated with a higher risk of SUP-related CDI than H2RA therapy in critically ill patients.
Abstract
Background/Aims: Proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs) are commonly prescribed for stress ulcer prophylaxis (SUP) in critically ill patients. Several studies have suggested that the use of PPIs is a potential risk factor for Clostridium difficile infection (CDI). We compared the incidences of CDI in the PPI group and H2RA group for SUP in critically ill patients. Methods: From August 2005 to July 2012, the incidences of CDI were retrospectively analyzed in patients who were admitted directly to intensive care units and stayed for more than 3 days. SUP-related CDI was defined as a CDI diagnosed during the SUP period. Patient clinical data were analyzed to identify potential risk factors for SUP-related CDI. Results: Of the 1,005 patients enrolled (444 patients received PPI and 561 received H2RA), 38 (3.8%) were diagnosed with SUP-related CDI. The incidence of SUP-related CDI was considerably higher in patients who received PPI than in those who received H2RA (6.7% vs 1.8%). PPI use for SUP (odds ratio [OR], 3.3; confidence interval [CI], 1.5 to 7.1; p=0.003) and diabetes mellitus (OR, 2.3; CI, 1.2 to 4.7; p=0.019) were independent risk factors for SUP-related CDI. Conclusions: PPI therapy is associated with a higher risk of SUP-related CDI than H2RA therapy in critically ill patients.
참고문헌 (27)
- Kenneally C, "Analysis of 30-day mortality for clostridium difficile-associated disease in the ICU setting", Chest, 132, pp.418~424 (2007)
- 도영석, "Long-Term Clinical Outcome of Clostridium difficile Infection in Hospitalized Patients: A Single Center Study", Intestinal research, 12(4), pp.299~305 (2014), 대한장연구학회
- Sesler JM, "Stress-related mucosal disease in the intensive care unit:an update on prophylaxis", AACN Adv Crit Care, 18, pp.119~126 (2007)
- Quenot JP, "Bedside adherence to clinical practice guidelines in the intensive care unit: the TECLA study", Intensive Care Med, 34, pp.1393~1400 (2008)
- Cook DJ, "Risk factors for gastrointestinal bleeding in critically ill patients: Canadian Critical Care Trials Group", N Engl J Med, 330, pp.377~381 (1994)
- Ben-Menachem T, "Prophylaxis for stress-related gastrointestinal hemorrhage: a cost effectiveness analysis", Crit Care Med, 24, pp.338~345 (1996)
- MacLaren R, "Cost-effectiveness of histamine receptor-2 antagonist versus proton pump inhibitor for stress ulcer prophylaxis in critically ill patients*", Crit Care Med, 42, pp.809~815 (2014)
- Lin PC, "The efficacy and safety of proton pump inhibitors vs histamine-2 receptor antagonists for stress ulcer bleeding prophylaxis among critical care patients:a meta-analysis", Crit Care Med, 38, pp.1197~1205 (2010)
- Jung R, "Proton-pump inhibitors for stress ulcer prophylaxis in critically ill patients", Ann Pharmacother, 36, pp.1929~1937 (2002)
- Lowe DO, "Proton pump inhibitors and hospitalization for Clostridium difficileassociated disease: a population-based study", Clin Infect Dis, 43, pp.1272~1276 (2006)
- Kim YG, "Proton pump inhibitor use and recurrent Clostridium difficile-associated disease: a case-control analysis matched by propensity score", J Clin Gastroenterol, 46, pp.397~400 (2012)
- Kwok CS, "Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis", Am J Gastroenterol, 107, pp.1011~1019 (2012)
- Beaulieu M, "Risk of Clostridium difficile-associated disease among patients receiving proton-pump inhibitors in a Quebec medical intensive care unit", Infect Control Hosp Epidemiol, 28, pp.1305~1307 (2007)
- Buendgens L, "Administration of proton pump inhibitors in critically ill medical patients is associated with increased risk of developing Clostridium difficileassociated diarrhea", J Crit Care, 29(696), pp.e11~e15 (2014)
- Barletta JF, "Proton pump inhibitors increase the risk for hospital-acquired Clostridium difficile infection in critically ill patients", Crit Care, 18, pp.714~ (2014)
- Rashid S, "Inappropriate use of gastric acid suppression therapy in hospitalized patients with clostridium difficile-associated diarrhea: a ten-year retrospective analysis", ISRN Gastroenterol, 2012, pp.902320~ (2012)
- Tleyjeh IM, "Association between proton pump inhibitor therapy and clostridium difficile infection:a contemporary systematic review and meta-analysis", PLoS One, 7, pp.e50836~ (2012)
- Alhazzani W, "Proton pump inhibitors versus histamine 2 receptor antagonists for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis", Crit Care Med, 41, pp.693~705 (2013)
- McCollum DL, "Detection, treatment, and prevention of Clostridium difficile infection", Clin Gastroenterol Hepatol, 10, pp.581~592 (2012)
- Gravel D, "Health care-associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: a Canadian Nosocomial Infection Surveillance Program Study", Clin Infect Dis, 48, pp.568~576 (2009)
- Marra AR, "Hospitalacquired Clostridium difficile-associated disease in the intensive care unit setting: epidemiology, clinical course and outcome", BMC Infect Dis, 7, pp.42~ (2007)
- Das R, "Glucocorticoids are associated with increased risk of short-term mortality in hospitalized patients with clostridium difficile-associated disease", Am J Gastroenterol, 105, pp.2040~2049 (2010)
- "ASHP therapeutic guidelines on stress ulcer prophylaxis", Am J Health Syst Pharm, 56, pp.347~379 (1999), ASHP Commission
- Muto CA, "A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use", Infect Control Hosp Epidemiol, 26, pp.273~280 (2005)
- Bishara J, "Obesity as a risk factor for Clostridium difficile infection", Clin Infect Dis, 57, pp.489~493 (2013)
- Huttunen R, "Obesity and the outcome of infection", Lancet Infect Dis, 10, pp.442~443 (2010)
- Falagas ME, "Effect of body mass index on the outcome of infections: a systematic review", Obes Rev, 10, pp.280~289 (2009)